- The“ Ion Chiricuta” Cancer Institute -Comprehensive Cancer Center
- The Institute of Public Health “Iuliu Moldovan„ Cluj-Napoca (ISPCN)
- S.C. Biona SRL
Defining the molecular transcriptomic profile for predicting the clinical outcome of anthracycline resistant breast cancers. Defining metastases in relation with the primary tumor. – Breast-OMICS
| Defining the molecular transcriptomic profile for predicting the clinical outcome of anthracycline resistant breast cancers. Defining metastases in relation with the primary tumor. From the informational website about a research project realized in the National Program of RDI.—PN II-partnership, BREAST-OMICS.|
Project description: BREAST-OMICS subscribes to Health area 4.1.3. Investigation and intervention methods based on molecular and cellular medicine, genomics and proteomics. This project is based on a highly complex partnership and seeks to develop the interdisciplinary sciences and high tech fields of genomics and proteomics in Romania, in the field of oncology. It would study tumor pathology and would use the newest technologies of genomics (microarray) and proteomics (protein-array) in breast cancer. The project will be carried on 36 months.It is estimated that 1 out of 8 (13%) women will develop breast cancer during their life and 1 out of 33 will die from it.
New concepts that resulted from the microarray technology in the discovery of biomarkers have shown that the pattern of transcription or the proteins can lead to a correct and timely diagnosis. By evaluating a single biomarker, these modern technologies (microarray, protein array) are capable of providing data about the whole transcriptome or proteome associated with cancer. They are able to evaluate thousands or tens of thousands of transcription products or proteins associated with the genes of interest. It is thus possible to study the differences between normal and tumor cells as well as the cellular mechanisms responsible for the development of cancer.
The resistance to cytostatics is one of the major problems in the treatment of cancer and the study of pharmacogenomics, which analyzes the simultaneous expression of the entire cellular transcript, is the only tool capable of clarifying the function of the cell after a treatment with cytostatics. The main aim of this project is to define of the molecular transcriptomic profile for the optimization of neoadjuvant anthracycline treatment in breast cancer. The objectives of the study are: the identification of a molecular signal through microarray, the analysis of differential gene expressions during anthracycline treatment; the validation through tissue array studies of the principal proteins associated to the studied genes; the evaluation of proangiogenic molecules in the development of the tumor and during treatment; the identification of a molecular target for angiogenesis and immune system modulators that will help define metastases and the primary tumor.